

# Retroviruses HIV/AIDS

#### Moses Masika; MBChB, MSc(TID)

Department of Medical Microbiology Virology Section

# Outline

- Classification
- Characteristics
- Distribution
- Pathogenesis
- Clinical manifestations
- Antiretroviral drugs
- Prevention strategies

# **Retroviridae family**

Subfamily	Genera	Species (Examples)
Orthoretrovirinae	Alpharetrovirus	e.g. Rous sarcoma virus
"	Betaretrovirus	e.g. Mouse mammary tumor virus
"	Deltaretrovirus	e.g. Human T-Lymphotropic virus(HTLV)
"	Epsilonretrovirus	Walleye dermal sarcoma virus
"	Gammaretrovirus	Viper retrovirus, Porcine type C oncovirus
"	Lentivirus	HIV-1, HIV-2, SIV, BIV, FIV, EIAIV
Spumaretrovirinae	Spumavirus	Equine foamy virus

### Retroviruses

#### **Unique features**:

- Undergo reverse transcription
- Three common genes, (*gag, pol, env*) in all retroviruses
- 2 copies of ss (+)sense RNA
- The only viruses which are truly diploid
- Genome does not serve directly as mRNA immediately after infection like for other (+)ssRNA viruses

# **HIV 1 Genome & Structure**



### Lentiviruses

- Genus: *Lentivirus*
- Slow progressive infections
- Species: HIV-1, HIV-2
  - Others:
    - Simian Immunodeficiency Virus (SIV)
    - Feline IV
    - Bovine IV
    - Equine Infectious Anemia Virus (EIAV) etc.
  - Individual viruses are restricted to a given host species

### HIV

**Baltimore**: Group 6 (*ssRNA* + *Reverse Transcriptase*)

**ICTV**(International Committee on Taxonomy of Viruses):

- Family: Retroviridae
- Genus: Lentiviruses
- **Species**: HIV-1 & HIV-2
- − **Groups:** HIV 1 − M, N, O & P
- Clades: HIV-1 (A-K, CRFs); HIV-2 (A-H)

# **HIV Subtypes (Clades)**



### **HIV Anatomy**



# **HIV Ligand-Cell Receptor interaction**

- Ligand: HIV glycoprotein gp120
- Cellular Receptor: CD4
- Co-receptors: CCR-5 or CXCR4
- HIV requires CD4 Receptor & a co-receptor for entry
- The receptors/co-receptors are expressed by immune cells (T-Cells and Antigens Presenting Cells)

# **HIV Co-receptors**



# **Retrovirus Replication Cycle**

- 1. Entry
- **Reverse Transcription** 2.
- Integration 3.
- Transcription 4.
- Translation 5.
- Maturation 6.
- Budding 7.



Video on HIV replication: https://www.youtube.com/watch?v=RO8MP3wMvqg

### HIV-1 vs HIV-2

	HIV-1	HIV-2
Distribution	Worldwide	West Africa, Europe & USA
Transmission	Easier transmission	Less easily transmitted
Progression	Faster progression	Slower progression
Origin	Related to SIV <sub>cpz</sub> (Chimpanzee SIV)	Related to SIV <sub>sm</sub> (Sooty Mangabey SIV)
Treatment	Responds to NNRTIs*	No response to NNRTIs: e.g. EFV, NVP

\*NNRTIs = Non-nucleoside Reverse Transcriptase Inhibitors

# Origin and Evolution of HIV

#### SIV<sub>cpz</sub> & HIV-1

#### SIV<sub>sm</sub> & HIV-2



Pan troglodytes (Chimpanzee)

#### **Cercobrus atys (Sooty mangabey)**

#### **Phylogenetic tree: Relationship between HIV-1 and SIVcpz**



### HIV-1

- AIDS 1<sup>st</sup> observed in 1981
- HIV identified in 1984
- HIV type 1 (HIV-1) & HIV type 2 (HIV-2)
- Causes AIDS: Acquired immunodeficiency syndrome:
  - Opportunistic infections: breakdown in the immune system
    - Quantitative decrease in T helper cell (CD4)

# HIV Map 2013

Worst-hit countries

Millions of cases

#### **People living with HIV**

35 million people, including 3.2 million children, are HIV-positive (2013 figures)



# Kenya

- Prevalence= 6%
- Burden: 1.6MPLHIV
- 192,000 infected children
- New infections: 102,000 p.a.
- Deaths: **58,000** p.a.



# **Key Populations**



• Key populations: 2% of the population; a third of all new infections (MOTs)

### **Transmission of HIV**

- Sexual contact: oral, anal, vaginal
- Sharps needles, blades
- Blood transfusion
- MTCT: during pregnancy, delivery, or breastfeeding









### **Risk factors: Acquisition of HIV Infection**

- Nature of the exposure (the dose of HIV inoculum)
- HIV virus genetics
- Host susceptibility to infection (host genetics e.g. delta 32 mutation)
- Routes of transmission (intravenous> Rectal > Vaginal).
- Mucosal inflammation (ulceration by STDs)

### **Sequence of events in HIV infection**

HIV infects CD4 cells (APC) **Disseminated** infection Specific immune Response (Ab, CMI) Clearance of most virus Some persistence a) Gradual loss of CD4 cells b) Destruction of lymphoid tissue

# **Clinical Features**

#### 1. Primary stage/Acute retroviral syndrome

- Seen in 10% of individuals a few weeks after exposure
- Acute seroconversion
- Presents with an 'flu-like' illness

#### 2. Asymptomatic stage

- Months to >10 years
- Incubation period is 8-10 years
- May present with lymphadenopathy
- 3. Symptomatic Stage
  - Opportunistic infections
- 4. Full-blown **AIDS** 
  - **AIDS** defining illnesses & cancers set in



# WHO HIV Staging

Stage	<b>Clinical Condition</b>	<b>CD4 Count</b>
	Primary HIV infection	
1	Asymptomatic	>500 cells/mm <sup>3</sup>
2	Mild Symptoms	350-500 cells/mm <sup>3</sup>
3	Symptomatic stage	200-350 cells/mm <sup>3</sup>
4	AIDS	<200 cells/mm <sup>3</sup>

# **Common Ols**

WHO STAGE	<b>Opportunistic Infections</b>
Primary Infection	Asymptomatic, Flu-like syndrome
Ι	Asymptomatic, Generalized Lymphadenopathy
II	Weight loss, Herpes zoster, Recurrent RTIs, Dermatitis, PPE (Pruritic popular Eruption)
III	Severe weight loss, Chronic diarrhea, Oral thrush, pTB, Severe bacteria infections
IV	Wasting, epTB, PCP, Toxoplasmosis, Cryptococcal meningitis, Encephalitis, Esophageal candidiasis, Cancers

### Herpes zoster



# **CDC** Staging

	Clinical Categories		
<b>CD 4 Categories</b>	A Asymptomatic	<b>B</b> Symptomatic	C AIDS
<b>1</b> (CD4>500)	A1	B1	C1
<b>2</b> (CD4 = 200-500)	A2	B2	C2
<b>3</b> (CD4<200)	A3	B3	C3

# **Opportunistic Infections**

- ProtozoalPCP pneumonia, toxoplasmosis, crytosporidiosis,Isosporiasis,
- FungalCandidiasis, CrytococcosisHistoplasmosis, Coccidiodomycosis
- BacterialTB, MAC,<br/>Salmonella septicaemiaMultiple or recurrent pyogenic bacterial infection<br/>(meningitis, pneumonia, pyomyositis etc.)

Viral CMV, HSV, VZV, JCV

Skin	Varicella zoster Herpes virus Kaposi sarcoma (associated with HHV-8)
Respiratory	PCP ( <i>Pneumocystis jirovecci</i> pneumonia) Tuberculosis Severe Bacterial pneumonia Kaposi sarcoma
GIT	Cryptosporidiosis Candidiasis Isosporiasis Kaposi sarcoma Cytomegalovirus
CNS	Cytomegalovirus (CMV) infection Herpes simplex (HSV) encephalitis Toxoplasmosis Cryptococcosis Severe bacterial meningitis Non-Hodgkins Lymphoma (NHL)

# **AIDS Defining Cancers**

- Kaposi's sarcoma (most frequent) observed in 20% of patients with AIDS.
  - Caused be Human Herpes Virus 8 (HHV-8).
- Malignant lymphomas frequently seen in AIDS patients.
- Cervical Cancer

# Kaposi's Sarcoma



# **Oral manifestations of HIV**

- Candidiasis
- Hairy leukoplakia (EBV)
- Kaposi sarcoma (HHV-8)
- Herpes labialis
- Periodontitis
- Aphthous ulcers (cause unknown)
- Oral warts (HPV)
- Xerostomia





Kaposi sarcoma

Oral thrush





#### Aphthous ulcers

Hairy leukoplakia

# **HIV Testing**

#### **Purpose of HIV Testing**

- o Diagnosis
- Surveillance
- Medical legal.
- Blood and organ transfusion
- o Travelling

### **HIV Tests**

- Antibody Tests
- Antigen tests
- Nucleic acid tests

# **Serological Tests**

- 1. Rapid HIV testing Initial Screening
- 2. ELISA Confirmation test
- 3. Western Blot Analysis Confirmation Test (rarely used nowadays)
- 4. p24 antigen Detection of a recent infection

# **Nucleic Acid Detection**

- Detection of HIV viral genome
- Very accurate, appropriate for infants< 18 months
- Can be:
  - 1. Qualitative HIV PCR to detect presence of infection
  - 2. Quantitative HIV PCR to measure viral load

# **HIV Antibody Rapid Test**



# **ELISA for HIV antibody**



### Microplate ELISA for HIV antibody: coloured wells indicate reactivity

#### **Baseline Investigations for HIV Positive Individuals**

Inv	estigation	Purpose
Immunology	CD4, CD8	Prognostic indicator Initiation of ART/Prophylaxis
HIV Virology	Antibody test (ELISA) Plasma viral load Resistance testing	Confirmation of infection Prognostic indicator Guide choice of ART
Microbiology	Syphilis Toxoplasmosis Hepatitis B & C	Detect latent disease Previous exposure, risk of recurrence Guide ART choice & initiation
Biochemistry	Renal Function Tests Liver Function Tests FBS, Lipid Profile	Baseline, Guide ART Subclinical disease, Baseline, Guide choice of ART Baseline, Guide ART
Hematology	Full Blood Count G6PD Deficiency	Detect hematologic abnormalities, Guide choice of ART Guide ART and prophylaxis for Opportunistic infections
Radiology	Chest X-ray Chest CT scan	Detect latent TB infection

### **Antiretrovirals - Drug targets**



### 1. Reverse Transcriptase Inhibitors

Block DNA synthesis from RNA by *Reverse transcriptase* aka *RNA-dependent DNA polymerase* 

*i. Nucleoside & Nucleotide Reverse Transcriptase Inhibitors (NRTIs):* 

Zidovudine, Lamivudine, Abacavir, Tenofovir

*ii. Non-Nucleoside RT Inhibitors* Nevirapine, Efavirenz, Etravirine





#### Zidovudine

Thymidine

### **2. Protease Inhibitors**

Bind *Protease* preventing protein cleavage hence blocking viral maturation

- Ritonavir
- Lopinavir
- Atazanavir
- Darunavir



#### 3. Integrase inhibitors

-Bind integrase preventing integration of HIV into host DNA e.g. *Raltegravir, Dolutegravir* 

#### 4. Fusion inhibitors

- Interfere with binding & fusion of HIV with cell membrane e.g. *Enfuvirtide*
- 5. CCR5 antagonists (against R5-tropic viruses)
  - Bind CCR5 co-receptor preventing attachment
  - e.g. Maraviroc

# **Prevention Targets**

- **GLOBAL**: 90-90-90 by 2020
- NATIONAL: Zero New Infections by 2030;
  75% reduction of new infections by 2020
- WHO: Universal Testing & Treatment (UTT)
- ULTIMATE: Eradicate HIV

# **Control & Prevention**

- Safer Sex practices
- Screening (blood & blood products, organ donors)
- Prevention of Mother to Child Transmission (MTCT)
- Early testing and linkage with care
- Treatment for prevention
- Voluntary Male Medical Circumcision (VMMC)
- Post-exposure prophylaxis (PEP)
- Pre-exposure prophylaxis (PreP)
- ?? Vaccines (Research in progress)

### **The Berlin Patient**



'I once had HIV!'

#### Functional cure for HIV

- March 2013: doctors described "*functional cure*" in a *HIV*-positive girl (*Mississippi baby*)
- Aggressive anti-retroviral drugs were started just 30 hours after birth
- There was no evidence, two years later, that HIV is present in her blood.
- Now back on ART after traces of HIV genome were detected

# References

 $\mathcal{D}$ 

- Jawetz, Melnick & Adelbergs Medical Microbiology
  26E, McGraw-Hill, LANGE Brooks, Carroll & Butel
- Virology: Principles & Applications, John Wiley & Sons Ltd – Carter & Saunders
- 3. <u>www.microbiologybook.org</u>
- 4. PUBMED: <u>https://www.ncbi.nlm.nih.gov/pubmed/</u>
- 5. Google Scholar: <u>www.scholar.google.com</u>

# QUEST IONS?







Masika Moses

**Medical Microbiology UoN** 

@MicrobiologyUoN